Report
Beyond the NRDL: Strategic Shifts in Mainland China’s Reimbursement Ecosystem
How Multinational Pharma Can Navigate an Evolving Market Access Landscape
The National Reimbursement Drug List (NRDL) remains the cornerstone of drug access in mainland China — but it’s no longer the only path.
As pricing pressures mount and cost-effectiveness thresholds grow tighter, multinational pharmaceutical companies (MNCs) are being forced to rethink their approach. High-cost, innovative therapies — many of which struggle to secure timely or viable inclusion in the NRDL — are increasingly finding alternative access routes.
This exclusive report from Clarivate explores the emerging multi-channel strategies transforming China’s reimbursement ecosystem — and what it means for pharma leaders who must balance access, speed, and pricing flexibility in one of the world’s most complex markets.
Inside the Report
A Changing Landscape: Why the NRDL can no longer serve as the sole reimbursement strategy — especially for innovative or high-value therapies.
Beyond the NRDL: Explore the growing role of local government initiatives, commercial insurance, patient access programs (PAPs), and public-private partnerships in shaping market entry.
Policy & Pricing Trends: Insights on how value-based procurement (VBP), diagnosis-related groups (DRGs), and health economic evaluations are redefining pricing benchmarks.
Firsthand Perspectives: Drawn from interviews and surveys with Chinese KOLs and stakeholders across policy, payer, and provider sectors.
Strategic Implications for MNCs: How to design flexible, scalable access strategies that align with China’s decentralizing healthcare policies — without compromising global pricing models.
Download the Full Report Now
Clarivate’s expert-driven analysis provides the insights you need to rethink market access strategy in China’s next era of healthcare reform.
